Physician profile
Rene Bermudez
NPI 1003895004
$3,547.30
in general payments reported to CMS, 2019-2025
21 companies · $816 in 2025
The $816 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.73 · 2020: $65.89 · 2021: $592 · 2022: $586 · 2023: $651 · 2024: $758 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.61 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,137.02 | 2021-2025 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $363.14 | 2019-2025 | |
| Lilly USA, LLC | $328.46 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $320.29 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $307.10 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $266.93 | 2021-2024 | Tremfya |
| Ucb, INC. | $152.68 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $127.93 | 2021-2025 | Dupixent |
| Organon LLC | $119.04 | 2025 | Nexplanon, Vtama |
| Genzyme Corporation | $80.80 | 2025 | |
| Leo Pharma INC. | $67.90 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $64.61 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $49.28 | 2024-2025 | Zoryve |
| Convatec INC. | $33.28 | 2024 | |
| Organogenesis INC. | $29.13 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.31 | 2025 | Cabtreo, Jublia |
| Biofrontera INC. | $19.45 | 2022 | |
| Amgen INC. | $19.40 | 2025 | Otezla |
| Verrica Pharmaceuticals INC. | $14.92 | 2025 | Ycanth |
| Pfizer INC. | $14.69 | 2023 | |
| Kerecis Limited | $9.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Bermudez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.